-transparent.png){kind=logo}
Oral doses of 1 to 100 mg amiflamine, a new reversible monoamine oxidase type A-selective inhibitor, were given for the first time in humans to six healthy men. No apparent pharmacologic effects were recorded until the 80 mg dose. After 100 mg, one subject developed symptoms indicative of an overdose. Amiflamine is extensively metabolized by two consecutive N-demethylations. The biotransformation patterns in plasma and urine were found to correlate with the debrisoquin metabolic ratio.
Related Publications
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
May 1993,
Biopharmaceutics & drug disposition,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
January 1988,
European journal of clinical pharmacology,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
January 1986,
Antimicrobial agents and chemotherapy,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
October 1988,
Antimicrobial agents and chemotherapy,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
December 1980,
Journal of pharmaceutical sciences,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
May 2007,
International journal of clinical pharmacology and therapeutics,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
January 1991,
European journal of clinical pharmacology,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
January 1987,
European journal of drug metabolism and pharmacokinetics,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
October 1993,
Arzneimittel-Forschung,
G Alván, and
C Graffner, and
M Grind, and
L L Gustafsson, and
J E Lindgren, and
C Nordin, and
S Ross, and
H Selander, and
B Siwers
January 2005,
Antimicrobial agents and chemotherapy,
